

We read with great interest the population-based study by Leher Gumber and colleagues examining trends in mortality due to haemophagocytic lymphohistiocytosis.1 This analysis provides valuable epidemiological insight into a rare but lethal condition and highlights important temporal and geographical variations.
Rheumatology
|11th Mar, 2026
|The New England Journal of Medicine
Rheumatology
|11th Mar, 2026
|The New England Journal of Medicine
Rheumatology
|11th Mar, 2026
|The Lancet
Rheumatology
|11th Mar, 2026
|The Lancet
Rheumatology
|11th Mar, 2026
|The Lancet
Rheumatology
|11th Mar, 2026
|The Lancet
Rheumatology
|11th Mar, 2026
|The Lancet